IGFBP7

Across TCGA pan-cancer cohorts, IGFBP7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGFBP7 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher IGFBP7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGFBP7 expression acts as an unfavorable survival marker.

LUSC, COAD, and CESC are the cancer types where IGFBP7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.149	0.661	.002	12	view →
COAD	DFS	Median	All	0.132	0.784	<.001	9	view →
CESC	DFS	Median	III,IV	0.240	0.726	.015	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IGFBP7–LUSC (DFS)

Open the LUSC breakdown →